コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nd/or the gastrointestinal tract (persistent vomiting).
2 e morphine and after excluding patients with vomit.
3 ing, eye bulging, bradycardia, cyanosis, and vomiting.
4 ad nausea and 15 (17%) versus three (5%) had vomiting.
5 spitalization, and frequency of diarrhea and vomiting.
6 complaints of epigastric abdominal pain and vomiting.
7 , headache, nausea, diarrhea, dizziness, and vomiting.
8 culitis accompanying with abdominal pain and vomiting.
9 of vision in her right eye, ocular pain and vomiting.
10 , but increases the occurrence of nausea and vomiting.
11 ED visits for gastroenteritis, diarrhea, and vomiting.
12 o an adverse event, oxygen desaturation, and vomiting.
13 e than glargine, were nausea, diarrhoea, and vomiting.
14 per abdominal pain radiating to the back and vomiting.
15 verse events (AEs) were fatigue, nausea, and vomiting.
16 ctory and somatosensory stimuli, nausea, and vomiting.
17 a 2-day history of abdominal distention and vomiting.
18 esented with a history of abdominal pain and vomiting.
19 low risk of chemotherapy-induced nausea and vomiting.
20 ss of consciousness, headache, and/or nausea/vomiting.
21 eduction in PTH) and self-reported nausea or vomiting.
22 s and specific symptoms of pain, nausea, and vomiting.
23 acial dysmorphisms, and periods of fever and vomiting.
24 by risk for chemotherapy-induced nausea and vomiting.
25 nted acutely with severe epigastric pain and vomiting.
26 om Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1
27 and promethazine after 24 hours (episodes of vomiting, 1 [IQR, 0-5] for metoclopramide vs 2 [IQR, 0-3
29 [3.7%] vs. 74 patients [6.2%]; P=0.006) and vomiting (100 patients [8.4%] vs. 194 patients [16.2%];
30 e nausea (16%), prolonged QT interval (12%), vomiting (11%), and dysgeusia (11%); most were </= grade
31 tigue (18 [56%] of 32 vs two [40%] of five), vomiting (12 [38%] of 32 vs zero), and anaemia (eight [2
32 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotr
33 s included nausea (eight [7%] vs one [<1%]), vomiting (13 [11%] vs one [<1%]), musculoskeletal pain (
36 6 [15%] of 233 patients vs five [2%] of 223; vomiting: 15 [6%] vs six [3%]; diarrhoea: 32 [14%] vs 15
38 [54% vs 23%; P < .001] and grade 3/4 nausea/vomiting [20% vs 11%; P = .03]), while rates of grade 3
39 [12%]), dyspepsia (24 [8%] vs 18 [6%]), and vomiting (21 [7%] vs 25 [8%]), with similar rates of stu
40 nts in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3.9%; P = .0
43 th neutropenia (30 [26.5%] of 113 patients), vomiting (22 [19.5%]), and leucopenia (17 [15.0%]) in th
45 CF versus LRD results were as follows: POD2 vomiting (28% vs 14%; P = 0.09), and significant increas
46 vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [18%]), and diarrhoea (22 [34%]
48 Rash (84 reports), itching (46 reports), and vomiting (30 reports) were the 3 most frequently occurri
49 xygen desaturation (353 patients [5.6%]) and vomiting (328 [5.2%]) were the most common of these adve
50 joint pains, 37 (5%) had nausea, 36 (4%) had vomiting, 34 (4%) had neuropathy, 23 (3%) had transamini
52 el-prednisone, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased
56 nausea (75%), fatigue (70%), anorexia (64%), vomiting (43%), weight loss (32%), and diarrhea (32%), w
60 6% [49 of 57]), ataxia (54% [29 of 54]), and vomiting (54% [29 of 54]) were common initial clinical m
61 up and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the chemo
62 not affect time to resolution of nausea and vomiting (64.5 vs 74.3 hours; P = 0.404) or consumption
63 and 8 [31%] patients in DRMPa200Z group) and vomiting (7 [12%] patients in MPa100Z group, 7 [11%] pat
65 30.7% [95% CI, 26.8%-34.7%]; P = .01) and no vomiting (87.1% [95% CI, 83.8%-90.0%) vs 78.0% [95% CI,
66 1.6% [95% CI, 37.4%-45.3%]; P < .001) and no vomiting (91.8% [95% CI, 89.0%-94.0%] vs 82.2% [95% CI,
67 sick with typical NoV infection symptoms of vomiting (93.4%), abdominal pain (90.4%), nausea (60.0%)
68 glucose levels in motion-induced nausea and vomiting, a finding that may provide insight into other
69 associated with reduced odds of posttussive vomiting, a marker of more clinically significant illnes
70 ose, he presented with headache, nausea, and vomiting; a brain magnetic resonance imaging scan showed
71 ts or who experience breakthrough nausea and vomiting; a recommendation to administer dexamethasone o
73 ge to the ENS or developmental defects cause vomiting, abdominal pain, constipation, growth failure,
74 number of symptoms and higher frequencies of vomiting, abdominal pain, swollen stomach, and loss of a
78 tient began to experience abdominal pain and vomiting after ingestion of egg approximately one day af
79 children treated with ondansetron continued vomiting after the administration of the therapy vs 93%
81 findings (>60 years, intoxication, headache, vomiting, amnesia, seizure, or trauma above the clavicle
84 prokinetic effects and significantly reduced vomiting and also improved other symptoms of diabetic ga
87 t requiring surgery [grade 3]; recurrence of vomiting and dehydration [grade 3]; diarrhoea and fever
88 s each year as a result of severe diarrhoea, vomiting and dehydration due to the actions of cholera t
89 s and other animals that is characterized by vomiting and diarrhea and caused by a variety of pathoge
101 53-year-old woman presented with nausea and vomiting and was noted to have an asymptomatic elevated
102 ; P = .068), and mild or greater severity of vomiting and/or diarrhea (20.0% vs. 37.5%; P = .074) wer
103 ovirus VLP vaccine reduced norovirus-related vomiting and/or diarrhea; field efficacy studies are pla
104 with acute gastroenteritis (diarrhea and/or vomiting) and 818 healthy controls frequency matched by
105 us, pain, presyncope, urinary retention, and vomiting) and one patient had a grade 4 adverse event (l
106 nal-reported morbidity (fever, diarrhea, and vomiting) and serious infectious events (SIEs) (gastroen
108 presents itself in association with nausea, vomiting, and abnormal sensitivity to light, noise, and
109 eumonia, ileus, and postoperative nausea and vomiting, and also improved recovery of bowel function,
111 than men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to vary by ge
112 despite severe side effects such as nausea, vomiting, and anorexia that compromise quality of life a
116 ose-limiting toxicities were grade 3 nausea, vomiting, and diarrhea in 2 patients, and grade 3 skin r
122 0(th) %ile of normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily
123 r (D2R) antagonist approved to treat nausea, vomiting, and headache in humans has potent in vitro and
124 e the early signs of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3% sodium
125 enia (n=4), diarrhoea (n=2), melena, stroke, vomiting, and intestinal infarction; all but one patient
126 ropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in pati
127 common (31 participants with nausea, 31 with vomiting, and one with diarrhoea), then oral pruritus af
130 stroesophageal reflux disease [GERD], nausea/vomiting, and pain) align with clinical symptomology and
132 physiological changes resulting in diarrhea, vomiting, and proinflammatory diseases, making both the
133 female, professional diver, reported nausea, vomiting, and systemic hives 20 to 30 minutes after inge
135 al with acute abdominal pain, diarrhoea, and vomiting, and was admitted to the hospital because of de
138 d adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed
140 -positive cases were younger, more likely to vomit (aOR, 2.6), to cough >/=14 days (aOR, 6.3), to hav
143 educed the half-time of gastric emptying and vomiting, as well as nausea, abdominal pain, bloating, a
144 oup had CPAP-related adverse events, such as vomiting, aspiration, and nasal, skin, or eye trauma.
145 inol and nabilone), which include nausea and vomiting associated with chemotherapy and appetite stimu
146 is (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in cancer patients
147 etic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic
150 ed trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s
151 symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s
152 n to prevent chemotherapy-induced nausea and vomiting (CINV) for patients undergoing high-dose chemot
153 the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely considered whe
156 definitions of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, f
157 sicians of six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and hair loss) within
162 who presented with acute epigastric pain and vomiting, diagnosed to have an incarcerated diaphragmati
164 minor adverse events were reported including vomiting, diarrhoea, cystitis, gastroenteritis, and blee
165 IGBs from the patient's body causes nausea, vomiting, discomfort, and even gastric mucous damage.
166 outh, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of
167 e associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infecti
168 revention of chemotherapy-induced nausea and vomiting during the 5-day (0-120 h) at-risk period after
169 revention of chemotherapy-induced nausea and vomiting during the at-risk period (120 h) after adminis
170 topenia, gastrointestinal events (diarrhoea, vomiting, dysgeusia, mucositis), fatigue, and hyponatrae
172 5% CI, 2.8-8.5; specificity, 97%), 2 or more vomiting episodes (LR, 3.6; 95% CI, 3.1-4.1; specificity
173 rrent or prior optic neuritis or intractable vomiting episodes more frequently, had shorter time to m
174 =2 vomiting episodes without diarrhea or 1-2 vomiting episodes plus 1-2 loose/liquid stools within 24
175 anded case definition of AGE (by adding >/=2 vomiting episodes without diarrhea or 1-2 vomiting episo
176 the Canadian CT Head Rule (>/=65 years; >/=2 vomiting episodes, amnesia >30 minutes, pedestrian struc
177 f skull fracture, GCS score of 13, 2 or more vomiting episodes, decrease in GCS score, and pedestrian
178 ry recall of postingestive aversive effects (vomiting), evoked by repeatedly touching the food with c
179 than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal res
181 fied acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced nee
182 2%] vs four [4%] postoperatively), nausea or vomiting (four [3%] vs six [4%] preoperatively; four [4%
183 were pulmonary embolism (four patients; 8%), vomiting (four; 8%), dehydration (three; 6%), and diarrh
184 rated gastric emptying (P < .03) and reduced vomiting frequency (by approximately 60%) and severity v
186 daily e-diaries, in which patients recorded vomiting frequency and symptom scores (nausea, abdominal
187 nts given relamorelin had a 75% reduction in vomiting frequency compared with baseline, but this diff
190 reduction in gastroenteritis, diarrhea, and vomiting GP in-hours consultations in children aged 0-4
191 vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (
192 neratinib vs 23 [2%] grade 3 with placebo), vomiting (grade 3: 47 [3%] vs five [<1%]), and nausea (g
194 l intake of ferrous iron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and cons
195 .89; 95% confidence interval [CI], .82-.97), vomiting (HR, 0.86; 95% CI, .75-.98), and fever (HR, 0.9
196 linking food exposure to typical symptoms of vomiting, hypotension, and diarrhea has lagged far behin
197 (eight grade 1 and five grade 2), nausea or vomiting in 15 patients (38%) (ten grade 1 and five grad
198 rse events were gastrointestinal (nausea and vomiting in four participants during pregnancy and three
201 revention of chemotherapy-induced nausea and vomiting in paediatric patients being treated with moder
203 olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemoth
204 revention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of
205 revention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of
208 findings suggest an effective treatment for vomiting in positive FPIES OFCs and allow for more confi
210 y end points were control of both nausea and vomiting in the acute posttreatment period (first 24 hou
212 , respectively), and incidence of nausea and vomiting in the PACU (4 of 19 [21.1%] and 6 of 24 [25%],
214 or less, parent-reported moderate or severe vomiting in the previous 24 h, parent-reported severe fe
219 gain resulting from compensatory behaviors (vomiting, laxative use, fasting, overexercise) was signi
220 he multivariate logistic model, a history of vomiting, lower platelet count, elevated aspartate amino
221 12), weight loss (LR, 4.7; 95% CI, 2.1-7.2), vomiting (LR, 4.6; 95% CI, 2.5-8.0), and swollen lymph n
223 erature, age, recession, wheeze, asthma, and vomiting (mnemonic STARWAVe; AUROC 0.81, 0.76-0.85) dist
228 ntly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, wh
229 (ie, complete protection, total control, no vomiting, no nausea, score of Functional Living Index-Em
230 ho achieved complete response (defined as no vomiting, no retching, and no use of rescue medication)
231 ns: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic
233 henia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the m
234 Hyperemesis gravidarum or severe nausea and vomiting of pregnancy affects women's physical, social a
235 east moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 m
238 oup (one had right loin pain, diarrhoea, and vomiting; one had malaise, headache, and chest pain; and
240 an 18 years, with at least three episodes of vomiting or diarrhoea in the preceding 24 h and fewer th
241 ion to hospital (32 were pneumonia, two were vomiting or feeding disorders, one was septicaemia, and
242 ), intense fatigue or weakness (n=495, 68%), vomiting or nausea (n=365, 50%), and diarrhoea (n=294, 4
243 to withhold opioids when ADEs (i.e., nausea/vomiting or oversedation) were present together with hig
244 point was rate of complete response (ie, no vomiting or rescue treatment) from days 2 to 5 after che
249 in eating disorder symptoms such as binging, vomiting, or laxative abuse were observed between the se
256 al functioning (P </= .001), less nausea and vomiting (P = .029 and .031, respectively) and less pain
259 ale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning,
261 ehydration (eight each [4%]), and diarrhoea, vomiting, pneumonia, and decreased appetite (four each [
264 ncluding migraines, postoperative nausea and vomiting (PONV), vertigo and morning sickness and observ
266 sia use, multimodal postoperative nausea and vomiting prophylaxis, multimodal sedation-hypnosis, and
268 dications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and
269 er of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95
273 health problems, such as acute gastritis and vomiting, road accident, high fever, or cardiovascular d
274 o, risk difference 3.7%, 95% CI 1.8-6.1) and vomiting (RR 2.43, 95% CI 1.83-3.23; p<0.0001; 8.0% osel
275 cores over the 14-day study period, trend in vomiting scores was better in the ondansetron group (P =
276 patient questionnaires showed a reduction in vomiting (severity), diarrhea (both incidence and severi
277 history of lower abdominal pain, nausea and vomiting since 2 days which was gradual in onset and pro
279 hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psycholo
281 p), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [2%] patients in each group); and nervous
283 In the 119 patients (58.3%) with baseline vomiting, twice-daily relamorelin significantly reduced
284 cal neurologic deficits, chest pain, nausea, vomiting, unintentional weight loss, or recent trauma.
285 usion, conjunctivitis, hiccups, diarrhea, or vomiting was associated with increased likelihood of con
290 based on the percentage of cases who stopped vomiting, was compared in cases who received parenteral
294 nt), and headache, dizziness, diarrhoea, and vomiting were the most frequent adverse events in patien
296 , retinal vein occlusion, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each).
297 nic trioxide because of grade 3 diarrhea and vomiting with concurrent grade 3 hypokalemia and hyponat
299 ampylobacter spp and Shigella spp, fever and vomiting with rotavirus, and vomiting with norovirus GII
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。